Three-year longitudinal assessment of denosumab’s efficacy and safety in postmenopausal osteoporosis: a 36-month real-world cohort study - Quiz - MDSpire

Three-year longitudinal assessment of denosumab’s efficacy and safety in postmenopausal osteoporosis: a 36-month real-world cohort study

  • By

  • Rong-Lin Xia

  • Chen Li

  • Li Wang

  • Ai-Jun Chao

  • Wei Wei

  • July 14, 2026

Share

Original Source(s)

Related Content